PMID: 6975769Nov 1, 1981Paper

A human leukocyte antigen identified by a monoclonal antibody

Human Immunology
A E BergerP Cresswell

Abstract

Leukocyte antigens of approximate molecular weight 200,000 daltons have been described in mouse, rat, and man. We describe here the reactivities of a monoclonal antibody, GAP 8.3, which identified such an antigen on human leukocytes. We found the leukocyte antigen H-T200 on T and B lymphocytes, granulocytes, monocytes, and platelets, but not on erythrocytes or nonhematopoetically derived cells. Resting and activated T cells had more antigen on their surfaces than did resting B lymphocytes and EBV-transformed B cells, respectively. The leukocyte antigen was detected on approximately 75% of bone marrow cells; cells of the erythroid series comprised the negative population. The GAP 8.3 antibody and its F(ab')2 fragments had no effect on in vitro stimulation of peripheral blood cells by mitogens or allogeneic cells. Antigen isolated from T cell lines had a higher electrophoretic mobility than did antigen from B cell lines; antigen from the myeloid line U937 comigrated with that from B cell lines. In addition, we detected very small but reproducible differences in the electrophoretic mobility of the antigen on two T cell lines.

References

Jan 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·I S TrowbridgeM J Bevan
Aug 1, 1976·European Journal of Immunology·I S Trowbridge, C Mazauskas
Jan 1, 1979·Immunological Reviews·F M BrodskyW F Bodmer
Jul 8, 1975·Biochemical and Biophysical Research Communications·J S Tkacz, O Lampen
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·L Y BourguignonS J Singer
Feb 1, 1979·International Journal of Cancer. Journal International Du Cancer·L C AnderssonC G Gahmberg
May 1, 1974·Archives of Oral Biology·Q T SmithB L Shapiro
Jul 1, 1974·European Journal of Biochemistry·W M Bonner, R A Laskey
Jun 1, 1971·Biochimica Et Biophysica Acta·T K Ray, G V Marinetti
May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·I S Trowbridge, M B Omary
Oct 1, 1980·The Journal of Experimental Medicine·M B OmaryH A Battifora
Feb 19, 1981·Nature·R L Coffman, I L Weissman
Mar 1, 1981·Cellular Immunology·D G FischerH S Koren
May 1, 1980·The Journal of Experimental Medicine·M B OmaryM P Scheid
Mar 1, 1980·Clinical Allergy·M J MorrisD J Lane

❮ Previous
Next ❯

Citations

Sep 1, 1990·Journal of Reproductive Immunology·A Jassim
Mar 1, 1993·Journal of Reproductive Immunology·A JassimY al-Zuhdi
Jan 1, 1987·Immunology Today·P Hersey, R Bolhuis
Oct 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·Z Bar-ShavitA J Kahn
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·A BárcenaC Martínez-A
Sep 1, 1992·The Journal of Experimental Medicine·I J MolinaE Remold-O'Donnell
Aug 1, 1988·Cellular Immunology·S J MentzerD V Faller
Jan 19, 1996·The Journal of Biological Chemistry·M AlessioR Sitia
Mar 15, 1988·International Journal of Cancer. Journal International Du Cancer·P HerseyG D'Alessandro
Jul 1, 1989·European Journal of Immunology·A JassimH Festenstein
May 1, 1988·European Journal of Immunology·C MorimotoS F Schlossman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.